Raineri Silvia, Mellor Jane
Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
Chronos Therapeutics, Oxford, United Kingdom.
Front Genet. 2018 Oct 23;9:493. doi: 10.3389/fgene.2018.00493. eCollection 2018.
Mutations in genes encoding enzymes of the tricarboxylic acid cycle often contribute to cancer development and progression by disrupting cell metabolism and altering the epigenetic landscape. This is exemplified by the isoforms of isocitrate dehydrogenase (IDH1/2), which metabolize isocitrate to α-Ketoglutarate (α-KG). Gain of function mutations in or result in reduced levels of α-KG as a result of increased formation of D-2-Hydroxyglutarate (2-HG). α-KG is an essential co-factor for certain histone and DNA demethylases, while 2-HG is a competitive inhibitor. These mutations are thought to result in hypermethylated histones and DNA which in turn alters gene expression and drives cancer progression. While this model seems to be generally accepted in the field, the exact molecular mechanisms still remain elusive. How much of this model has been rigorously demonstrated and what is just being assumed? Are the effects genome-wide or focused on specific loci? This aims at elucidating the key questions that remain to be addressed, the experimental techniques that could be used to gain further insight into the molecular mechanisms involved and the additional consequences of these mutations beyond DNA and protein methylation.
编码三羧酸循环酶的基因突变常常通过扰乱细胞代谢和改变表观遗传格局,促进癌症的发生和发展。异柠檬酸脱氢酶(IDH1/2)的同工型就是一个例子,它将异柠檬酸代谢为α-酮戊二酸(α-KG)。IDH1或IDH2的功能获得性突变会导致D-2-羟基戊二酸(2-HG)生成增加,从而使α-KG水平降低。α-KG是某些组蛋白和DNA去甲基化酶的必需辅助因子,而2-HG是一种竞争性抑制剂。这些突变被认为会导致组蛋白和DNA高度甲基化,进而改变基因表达并推动癌症进展。虽然这个模型在该领域似乎已被普遍接受,但确切的分子机制仍然难以捉摸。这个模型中有多少已得到严格证明,哪些只是假设?这些影响是全基因组范围的,还是仅针对特定基因座?本文旨在阐明仍有待解决的关键问题、可用于进一步深入了解相关分子机制的实验技术,以及这些突变除了DNA和蛋白质甲基化之外的其他后果。